Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2004

View Archived Issues

Integrase inhibitor boosts cellular immunity to suppress HIV-1 replication in monkeys

Atorvastatin improves erectile function in men with hypercholesterolemia-related ED

Vernalis and Endo in Frova license agreement

Zelnorm recommended for approval for chronic constipation with restrictions

Bone Care International and Cardinal Health in Hectorol copromotion

Series B financing at Trubion to fund pipeline advancement

New phase IIa trials for XP-13512, additional phase I results

First patients enrolled in phase I trial of new HIV vaccine

Shelf registration for Biomira

Positive phase II results for Alista in premenopausal women with FSAD

Phase I trial for new formulation of 17-AAG in multiple myeloma

Zonagen reports Androxal phase I/II study results

Results of first phase I trial for propofol lingual spray

Phase II protocol for NX-1207 accepted by FDA

Elafin completes preclinical testing

Enrollment completed in phase III trial of orBec

Antiviral activity of a 2-5A agonist in cells from HIV-positive patients

Preliminary data on the effects and safety of TA-NIC in smokers

Promising results reported for APD-356 in the treatment of obesity

Melanocortin MC4 receptor agonists described in patent literature

Lilly claims TGF-beta signal transduction inhibitors

Phosphotidylinositol 3-kinase inhibitors described by Chiron

Boehringer Ingelheim discloses anticholinergic compounds

Several BMS patents describe KCNQ potassium channel openers

Divalent metal chelator displays neuroprotective effects on neurons from AD patients

Chinese herbal extract reduces neuron damage in in vitro models of brain aging

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...